<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490956</url>
  </required_header>
  <id_info>
    <org_study_id>RabiesPID</org_study_id>
    <nct_id>NCT02490956</nct_id>
  </id_info>
  <brief_title>Diagnostic Immunization With Rabies Vaccine in Patients With PID</brief_title>
  <official_title>Diagnostic Immunization With Rabies Vaccine in Patients With Primary Immunodeficiency Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate diagnostic immunization protocol of rabies vaccine&#xD;
      for diagnosis the patients with primary immunodeficiency disorders and study humoral and&#xD;
      cellular immune response to rabies vaccine in patients with primary immunodeficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective Primary objective&#xD;
&#xD;
      : To study diagnostic immunization protocol of rabies vaccine for diagnosis the patients with&#xD;
      primary immunodeficiency disorders. Secondary objective&#xD;
&#xD;
        -  To study humoral and cellular immune response to rabies vaccine in patients with primary&#xD;
           immunodeficiency.&#xD;
&#xD;
        -  To study anti-rabies immunization protocol in patients with primary immunodeficiency&#xD;
           disorders.&#xD;
&#xD;
      Population Case group: Twenty primary immunodeficiency disease patients that are diagnosed,&#xD;
      treated and followed at Allergy and Immunology unit, Department of Pediatrics, Faculty of&#xD;
      Medicine, Chulalongkorn University.&#xD;
&#xD;
      Control group: Twenty healthy subjects who have no underlying disease and age-matched with&#xD;
      case patients. Inclusion and exclusion criteria&#xD;
&#xD;
      Vaccine :&#xD;
&#xD;
        -  Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular&#xD;
&#xD;
        -  Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year&#xD;
           later on days 360 and 363&#xD;
&#xD;
      Immunological evaluations :&#xD;
&#xD;
        1. Humoral immune response :&#xD;
&#xD;
           on 5 ml blood samples will be collected for antibody determination days 0, 14, 28, 90,&#xD;
           360, 367 and 374. Neutralizing antibodies will be determined blindly using the rapid&#xD;
           fluorescent focus inhibition test (RFFIT) at Queen Saovabha Memorial Institute. Rabies&#xD;
           neutralizing antibody will be reported in IU/ml The protective antibody level are&#xD;
           defined rabies neutralizing antibody ≥ 0.5 IU/ml .&#xD;
&#xD;
        2. Cellular mediated immune response :&#xD;
&#xD;
      On 5 ml blood samples will be collected for antibody determination days 14, 28, 90, 360, 367&#xD;
      and 374. Lymphocyte proliferation response to rabies antigen will be determined by using&#xD;
      3H-thymidine incorporation assay.&#xD;
&#xD;
      The responder criteria are defined as stimulation index (SI index) ≥ 2.0 was considered as&#xD;
      evidence of antigen-induced lymphocyte proliferation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rabies neutralizing antibody titer (RFFIT test)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte proliferation response to rabies antigen (3H-Thymidine incorporation assay)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Primary Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>Rabies vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular&#xD;
Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Verorab® (PVRV; Purified Vero Cell Vaccine)</intervention_name>
    <description>Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular&#xD;
Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363</description>
    <arm_group_label>Rabies vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Case group&#xD;
&#xD;
               1. Patient with primary immunodeficiency diseases who follows up at Division of&#xD;
                  pediatric allergy and immunology unit, King Chulalongkorn Memorial Hospital&#xD;
&#xD;
               2. Subject or father/mother/legally acceptable representative properly informed&#xD;
                  about the study and having signed the informed consent form.&#xD;
&#xD;
               3. Subject is able to comply with the follow-up schedule of the protocol&#xD;
&#xD;
          -  Control group&#xD;
&#xD;
               1. Subject is healthy (from history and physical examination)&#xD;
&#xD;
               2. Subject do not has underlying diseases.&#xD;
&#xD;
               3. Subject do not has primary and secondary immunodeficiency diseases&#xD;
&#xD;
               4. Subject is not receiving immunosuppressive therapy or cytotoxic drugs&#xD;
&#xD;
               5. Subject or father/mother/legally acceptable representative properly informed&#xD;
                  about the study and having signed the informed consent form.&#xD;
&#xD;
               6. Subject is able to comply with the follow-up schedule of the protocol&#xD;
&#xD;
               7. Age more than 12 month old to 60 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Reported history of previous rabies immunization or Rabies neutralizing antibody&#xD;
             (Rabies Nab) &gt; 0.5 IU/ml&#xD;
&#xD;
          2. Subject is unable to comply with the follow-up schedule of the protocol&#xD;
&#xD;
          3. Pregnancy&#xD;
&#xD;
          4. Body temperature more than 38 degree celcius at screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Narissara - Suratannon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Narissara - Suratannon, MD</last_name>
    <phone>6622564455</phone>
    <phone_ext>14,15</phone_ext>
    <email>mayzped@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Allergic and Immunology , Department of Pediatrics, Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narissara Suratannon, MD</last_name>
      <phone>+66812950190</phone>
      <email>mayzped@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Suvanee Charoenlap, MD</last_name>
      <phone>+66814729600</phone>
      <email>suvanee171@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2015</study_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Narissara Suratannon</investigator_full_name>
    <investigator_title>Faculty of Medicine, Chulalongkorn university</investigator_title>
  </responsible_party>
  <keyword>Diagnostic immunization with rabies vaccine</keyword>
  <keyword>Primary immunodeficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

